

ACT No. 100

2017 Regular Session

HOUSE BILL NO. 225

BY REPRESENTATIVE PEARSON

1 AN ACT

2 To amend and reenact R.S. 40:961(25) and to enact R.S. 40:964(Schedule I)(A)(57) through
3 (60), (D)(5), (Schedule II)(B)(29), (F)(2), and (Schedule V)(D)(4) and (F)(1),
4 relative to the Uniform Controlled Dangerous Substances Law; to amend the
5 definition of marijuana; to add certain substances to Schedules I, II, and V; and to
6 provide for related matters.

7 Be it enacted by the Legislature of Louisiana:

8 Section 1. R.S. 40:961(25) is hereby amended and reenacted and R.S.
9 40:964(Schedule I)(A)(57) through (60), (D)(5), (Schedule II)(B)(29), (F)(2), and (Schedule
10 V)(D)(4) and (F)(1) are hereby enacted to read as follows:

11 §961. Definitions

12 As used in this Part, the following terms shall have the meaning ascribed to
13 them in this Section unless the context clearly indicates otherwise:

14 * * *

15 (25) "Marijuana" means all parts of plants of the genus Cannabis, whether
16 growing or not; the seeds thereof; the resin extracted from any part of such plant; and
17 every compound, manufacture, salt, derivative, mixture, or preparation of such plant,
18 its seeds or resin, but shall not include the mature stalks of such plant, fiber produced
19 from such stalks, oil or cake made from the seeds of such plant, any other compound,
20 manufacture, salt, derivative, mixture, or preparation of such mature stalks (except
21 the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant

1 which is incapable of germination, or cannabidiol when contained in a drug product
2 approved by the United States Food and Drug Administration.

3 * * *

4 §964. Composition of schedules

5 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.
6 40:962, consist of the following drugs or other substances, by whatever official
7 name, common or usual name, chemical name, or brand name designated:

8 SCHEDULE I

9 A. Opiates. Unless specifically excepted or unless listed in another schedule,
10 any of the following opiates, including their isomers, esters, ethers, salts, or salts of
11 isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers,
12 or salts is possible within the specific chemical designation:

13 * * *

14 *(57) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
15 methylbenzamide)

16 *(58) Furanylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-
17 2-carboxamide)

18 *(59) Acrylfentanyl (N-[1-(2-phenylethyl)piperidin-4-yl]-N-
19 phenylacrylamide)

20 *(60) 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]-benzamide
21 (AH-7921)

22 * * *

23 D. Depressants. Unless specifically excepted or unless listed in another
24 schedule, any material, compound, mixture, or preparation which contains any
25 quantity of the following substances having a depressant effect on the central
26 nervous system, including its salts, isomers, and salts of isomers whenever the
27 existence of such salts, isomers, and salts of isomers is possible within the specific
28 chemical designation:

29 * * *

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

(5) Etizolam

* * *

SCHEDULE II

* * *

B. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

* * *

(29) Thiafentanil

* * *

F. Hallucinogenic substances:

* * *

(2) Dronabinol [delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the United States Food and Drug Administration.

* * *

SCHEDULE V

* * *

D. Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

* * *

(4) Brivaracetam (2-[2-oxo-4-propylpyrrolidin-1-yl]butanamide), also referred to as BRV; UCB-34714; Briviact.

* * *

1 F. Hallucinogens

2 (1) (2-[3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-

3 benzenediol) cannabidiol when contained in a drug product approved by the United

4 States Food and Drug Administration.

SPEAKER OF THE HOUSE OF REPRESENTATIVES

PRESIDENT OF THE SENATE

GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: _____